OTCMKTS:MKGAF

MERCK Kommanditgesellschaft auf Aktien Competitors

$174.00
+8.20 (+4.95 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$174.00
$174.38
50-Day Range
$160.60
$177.75
52-Week Range
$107.50
$182.85
Volume78 shs
Average Volume461 shs
Market Capitalization$22.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.7

Competitors

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Vs. ZTS, BAYRY, VRTX, TAK, REGN, and ALXN

Should you be buying MKGAF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to MERCK Kommanditgesellschaft auf Aktien, including Zoetis (ZTS), Bayer Aktiengesellschaft (BAYRY), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), and Alexion Pharmaceuticals (ALXN).

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MERCK Kommanditgesellschaft auf Aktien10.92%14.29%5.90%
Zoetis25.50%63.89%14.99%

Risk and Volatility

MERCK Kommanditgesellschaft auf Aktien has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Insider & Institutional Ownership

92.5% of Zoetis shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares MERCK Kommanditgesellschaft auf Aktien and Zoetis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MERCK Kommanditgesellschaft auf Aktien$18.09 billion1.24$1.48 billionN/AN/A
Zoetis$6.26 billion13.02$1.50 billion$3.6447.13

Zoetis has lower revenue, but higher earnings than MERCK Kommanditgesellschaft auf Aktien.

Analyst Ratings

This is a breakdown of current ratings for MERCK Kommanditgesellschaft auf Aktien and Zoetis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MERCK Kommanditgesellschaft auf Aktien0000N/A
Zoetis05902.64

Zoetis has a consensus target price of $178.1818, indicating a potential upside of 3.87%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Summary

Zoetis beats MERCK Kommanditgesellschaft auf Aktien on 10 of the 11 factors compared between the two stocks.

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) and Bayer Aktiengesellschaft (OTCMKTS:BAYRY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Bayer Aktiengesellschaft's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MERCK Kommanditgesellschaft auf Aktien10.92%14.29%5.90%
Bayer Aktiengesellschaft-22.32%14.23%5.01%

Risk and Volatility

MERCK Kommanditgesellschaft auf Aktien has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Bayer Aktiengesellschaft has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Valuation & Earnings

This table compares MERCK Kommanditgesellschaft auf Aktien and Bayer Aktiengesellschaft's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MERCK Kommanditgesellschaft auf Aktien$18.09 billion1.24$1.48 billionN/AN/A
Bayer Aktiengesellschaft$48.23 billion1.27$4.58 billion$1.779.31

Bayer Aktiengesellschaft has higher revenue and earnings than MERCK Kommanditgesellschaft auf Aktien.

Analyst Recommendations

This is a summary of current recommendations and price targets for MERCK Kommanditgesellschaft auf Aktien and Bayer Aktiengesellschaft, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MERCK Kommanditgesellschaft auf Aktien0000N/A
Bayer Aktiengesellschaft18702.38

Summary

Bayer Aktiengesellschaft beats MERCK Kommanditgesellschaft auf Aktien on 5 of the 8 factors compared between the two stocks.

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MERCK Kommanditgesellschaft auf Aktien10.92%14.29%5.90%
Vertex Pharmaceuticals38.51%28.55%20.68%

Risk and Volatility

MERCK Kommanditgesellschaft auf Aktien has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares MERCK Kommanditgesellschaft auf Aktien and Vertex Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MERCK Kommanditgesellschaft auf Aktien$18.09 billion1.24$1.48 billionN/AN/A
Vertex Pharmaceuticals$4.16 billion13.37$1.18 billion$4.2950.12

MERCK Kommanditgesellschaft auf Aktien has higher revenue and earnings than Vertex Pharmaceuticals.

Analyst Recommendations

This is a summary of current recommendations and price targets for MERCK Kommanditgesellschaft auf Aktien and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MERCK Kommanditgesellschaft auf Aktien0000N/A
Vertex Pharmaceuticals041612.86

Vertex Pharmaceuticals has a consensus price target of $293.4737, indicating a potential upside of 36.49%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Summary

Vertex Pharmaceuticals beats MERCK Kommanditgesellschaft auf Aktien on 10 of the 12 factors compared between the two stocks.

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Takeda Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MERCK Kommanditgesellschaft auf Aktien10.92%14.29%5.90%
Takeda Pharmaceutical3.04%13.46%5.02%

Risk and Volatility

MERCK Kommanditgesellschaft auf Aktien has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Insider and Institutional Ownership

3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares MERCK Kommanditgesellschaft auf Aktien and Takeda Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MERCK Kommanditgesellschaft auf Aktien$18.09 billion1.24$1.48 billionN/AN/A
Takeda Pharmaceutical$30.20 billion1.76$407.02 million$1.789.48

MERCK Kommanditgesellschaft auf Aktien has higher earnings, but lower revenue than Takeda Pharmaceutical.

Analyst Recommendations

This is a summary of current recommendations and price targets for MERCK Kommanditgesellschaft auf Aktien and Takeda Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MERCK Kommanditgesellschaft auf Aktien0000N/A
Takeda Pharmaceutical02002.00

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MERCK Kommanditgesellschaft auf Aktien10.92%14.29%5.90%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Risk and Volatility

MERCK Kommanditgesellschaft auf Aktien has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares MERCK Kommanditgesellschaft auf Aktien and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MERCK Kommanditgesellschaft auf Aktien$18.09 billion1.24$1.48 billionN/AN/A
Regeneron Pharmaceuticals$7.86 billion6.77$2.12 billion$21.4723.14

Regeneron Pharmaceuticals has lower revenue, but higher earnings than MERCK Kommanditgesellschaft auf Aktien.

Analyst Recommendations

This is a summary of current recommendations and price targets for MERCK Kommanditgesellschaft auf Aktien and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MERCK Kommanditgesellschaft auf Aktien0000N/A
Regeneron Pharmaceuticals051402.74

Regeneron Pharmaceuticals has a consensus price target of $656.3810, indicating a potential upside of 32.14%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Summary

Regeneron Pharmaceuticals beats MERCK Kommanditgesellschaft auf Aktien on 9 of the 11 factors compared between the two stocks.

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MERCK Kommanditgesellschaft auf Aktien10.92%14.29%5.90%
Alexion Pharmaceuticals16.32%23.16%14.76%

Risk and Volatility

MERCK Kommanditgesellschaft auf Aktien has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares MERCK Kommanditgesellschaft auf Aktien and Alexion Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MERCK Kommanditgesellschaft auf Aktien$18.09 billion1.24$1.48 billionN/AN/A
Alexion Pharmaceuticals$4.99 billion7.55$2.40 billion$9.7417.50

Alexion Pharmaceuticals has lower revenue, but higher earnings than MERCK Kommanditgesellschaft auf Aktien.

Analyst Recommendations

This is a summary of current recommendations and price targets for MERCK Kommanditgesellschaft auf Aktien and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MERCK Kommanditgesellschaft auf Aktien0000N/A
Alexion Pharmaceuticals015402.21

Alexion Pharmaceuticals has a consensus price target of $159.3158, indicating a potential downside of 6.52%. Given Alexion Pharmaceuticals' higher probable upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Summary

Alexion Pharmaceuticals beats MERCK Kommanditgesellschaft auf Aktien on 10 of the 11 factors compared between the two stocks.


MERCK Kommanditgesellschaft auf Aktien Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zoetis logo
ZTS
Zoetis
1.8$171.55+2.3%$81.48 billion$6.26 billion50.91Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Bayer Aktiengesellschaft logo
BAYRY
Bayer Aktiengesellschaft
1.0$16.47+0.9%$61.44 billion$48.23 billion-6.15Upcoming Earnings
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$215.01+0.9%$55.66 billion$4.16 billion27.15Analyst Upgrade
Insider Selling
Analyst Revision
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$16.87+1.5%$53.24 billion$30.20 billion56.24Upcoming Earnings
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$496.75+0.4%$53.22 billion$7.86 billion18.16Earnings Announcement
Analyst Report
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$170.43+0.3%$37.67 billion$4.99 billion39.82Analyst Upgrade
Analyst Revision
Shiseido logo
SSDOY
Shiseido
0.9$73.64+1.0%$29.41 billion$10.38 billion-253.91Upcoming Earnings
Astellas Pharma logo
ALPMY
Astellas Pharma
1.7$15.40+0.8%$28.67 billion$11.97 billion22.32
BeiGene logo
BGNE
BeiGene
1.1$311.97+0.7%$28.61 billion$428.21 million-15.44Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Gap Up
Takeda Pharmaceutical logo
TKPYY
Takeda Pharmaceutical
1.0$16.87+1.5%$26.36 billion$15.99 billion12.11High Trading Volume
News Coverage
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$40.97+0.2%$24.87 billionN/A0.00Upcoming Earnings
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.40+0.5%$24.53 billion$804.57 million28.99Earnings Announcement
Analyst Revision
News Coverage
Genmab A/S logo
GNMSF
Genmab A/S
0.6$381.17+5.9%$23.51 billion$804.57 million5.41Gap Down
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$87.93+2.2%$19.70 billion$1.30 billion24.02Earnings Announcement
Gap Up
UCB logo
UCBJF
UCB
1.0$98.00+0.0%$19.06 billion$5.50 billion16.84
CureVac logo
CVAC
CureVac
0.7$100.40+6.4%$18.77 billionN/A0.00Increase in Short Interest
Gap Up
Catalent logo
CTLT
Catalent
1.7$107.56+1.3%$18.32 billion$3.09 billion68.51Earnings Announcement
Analyst Upgrade
News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.88+5.6%$15.55 billion$3.07 billion-57.68Earnings Announcement
News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$131.30+0.6%$15.43 billion$219.75 million-16.77Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.77+1.1%$14.21 billion$1.70 billion17.80Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$158.14+1.6%$14.10 billion$12.98 million-52.19Upcoming Earnings
Insider Selling
OPHLF
Ono Pharmaceutical
1.1$25.90+3.3%$13.32 billion$2.69 billion23.55Upcoming Earnings
Grifols logo
GRFS
Grifols
1.3$18.23+1.4%$12.53 billion$5.71 billion16.28Earnings Announcement
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$71.02+0.5%$11.81 billion$2.32 billion58.69
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.40+1.1%$11.36 billion$16.89 billion-2.83Analyst Downgrade
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.08+1.1%$10.06 billion$8.60 billion-5.15Earnings Announcement
Analyst Report
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$174.59+1.0%$9.93 billion$2.16 billion55.08Earnings Announcement
Analyst Report
Insider Selling
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$37.15+4.2%$9.57 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Decrease in Short Interest
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$195.42+1.7%$8.75 billion$1.45 billion18.49Earnings Announcement
Analyst Report
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$114.53+1.0%$7.73 billion$103.71 million-26.09Earnings Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$144.00+4.7%$7.39 billion$3.34 million-18.70Earnings Announcement
News Coverage
Gap Up
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$48.03+3.2%$7.17 billion$40.56 million-14.09Earnings Announcement
Analyst Report
News Coverage
Gap Up
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$132.90+0.0%$7.14 billion$14.98 million-16.19Analyst Revision
News Coverage
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.38+1.1%$6.91 billion$87.99 million-79.02Earnings Announcement
Analyst Revision
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30Earnings Announcement
Analyst Downgrade
Evotec logo
EVTCY
Evotec
0.5$81.29+2.3%$6.69 billion$500.07 million451.64Upcoming Earnings
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$74.57+0.1%$5.95 billion$380.83 million-9.54Earnings Announcement
News Coverage
Perrigo logo
PRGO
Perrigo
2.2$42.96+0.7%$5.74 billion$4.84 billion-715.88Upcoming Earnings
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.20+0.9%$5.69 billion$150,000.00-18.96Upcoming Earnings
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.93+1.8%$5.54 billion$66.51 million17.51Analyst Report
News Coverage
Allakos logo
ALLK
Allakos
1.7$100.93+1.8%$5.40 billionN/A-36.84Upcoming Earnings
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.54+2.2%$5.15 billion$1.12 billion76.13Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Up
Galapagos logo
GLPG
Galapagos
1.3$75.04+1.5%$4.92 billion$1.00 billion-11.37News Coverage
Gap Up
Schrödinger logo
SDGR
Schrödinger
1.6$68.37+1.7%$4.79 billion$85.54 million0.00Upcoming Earnings
Analyst Downgrade
Insider Selling
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$71.44+0.9%$4.43 billionN/A-5.82Upcoming Earnings
Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.07+4.0%$4.39 billion$6.87 million-7.25Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
I-Mab logo
IMAB
I-Mab
1.2$59.28+0.5%$4.27 billion$4.31 million-2.05Analyst Revision
Hypera logo
HYPMY
Hypera
0.9$6.54+0.3%$4.14 billion$834.89 million15.21
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$64.79+2.7%$3.93 billion$806.43 million-9.18Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.23+3.3%$3.91 billion$204.89 million-32.79Analyst Revision
News Coverage
Gap Up
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.